Results 61 to 70 of about 5,040,500 (260)
Molecular Oncology, EarlyView.Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
The Next Linear Collider test accelerator: status and results
, 1996 At SLAC, the authors are pursuing the design of a Next Linear Collider (NLC) which would begin with a center-of-mass energy of 0.5 TeV, and would be upgradable to 1.0 TeV and beyond.
Ruth, Ronald D, Ruth, R. D.
core
Oncogenic DMTF1β promotes cancer cell motility by regulating autophagy through ULK1 stabilization
Molecular Oncology, EarlyView.In the current study, we demonstrate that the oncogene DMTF1β regulates ULK1 stability by reducing its proteasomal degradation in cancer cells. This stabilization enables ULK1 to induce autophagy, which in turn facilitates cancer cell migration. Consequently, reduced DMTF1β levels lead to decreased autophagy and impaired cancer cell migration.
Jun Xu +13 more
wiley +1 more source
A test accelerator for the next linear collider
, 1993 At SLAC, the authors are pursuing the design of a Next Linear Collider (NLC) which would begin with a center-of-mass energy of 0.5 TeV, and be upgradable to at least 1.0 TeV.
Lavine, T. +35 more
core
Loss of proton‐sensing TDAG8 increases tumor progression in mouse models of colon cancer
Molecular Oncology, EarlyView.Loss of the pH‐sensing receptor TDAG8 accelerates colorectal cancer progression in mice. Animals lacking TDAG8 expression had increased tumor growth, DNA damage, and recruitment of tumor‐associated immune cells, including macrophages, neutrophils, and monocytes.
Ermanno Malagola +11 more
wiley +1 more source
The Next Linear Collider Test Accelerator
, 1993 During the past several years, there has been tremendous progress the development of the RF system and accelerating structures for a Next Linear Collider (NLC).
Adolphsen, C., Ruth, R. D., Bane, K.
core
Molecular Oncology, EarlyView.Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim +3 more
wiley +1 more source
FEBS Open Bio, EarlyView.Time‐resolved X‐ray solution scattering captures how proteins change shape in real time under near‐native conditions. This article presents a practical workflow for light‐triggered TR‐XSS experiments, from data collection to structural refinement. Using a calcium‐transporting membrane protein as an example, the approach can be broadly applied to study ...
Fatemeh Sabzian‐Molaei +3 more
wiley +1 more source
Mode propagation in an iris type accelerator section loaded with single heavily HOM-damped cells
, 1994 The wakefield effects in accelerator sections for future linear colliders will be reduced either by damping by detuning or by a combination of both. For the DESY/THD linac [1] it is forseen to employ heavily HOM-damped cells to provide a strong coupling ...
Müller, Wolfgang F. O. +5 more
core
FEBS Open Bio, EarlyView.Erythropoietin administration suppresses hepatic soluble epoxide hydrolase (sEH) expression, leading to increased CYP‐derived epoxides. This is associated with a shift in hepatic macrophage polarization characterized by reduced M1 markers and increased M2 markers, along with reduced hepatic inflammation, suppressed hepatic lipogenesis, and attenuated ...
Takeshi Goda +12 more
wiley +1 more source